

## DAFTAR PUSTAKA

- ACS, 2022. Lung Cancer Early Detection , Diagnosis , and Staging Can Lung Cancer Be Found Early ? *Am. Cancer Soc.* 1–41.
- Alali, M., & Saifo, M., 2023. Optimizing the Treatment for Advanced Non–Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review. *J. Immunother. Precis. Oncol.* 6: 140–149. doi:10.36401/JIPO-22-29
- Alduais, Y., 2023. Non-small cell lung cancer (NSCLC) 8: 10–14.
- Antony, V.B., Loddenkemper, R., Astoul, P., Boutin, C., Goldstraw, P., Hott, J., et al., 2001. Management of malignant pleural effusions. *Eur. Respir. J.* 18: 402–419. doi:10.1183/09031936.01.00225601
- Araki, T., Yashima, H., Shimizu, K., Aomori, T., Hashita, T., Kaira, K., et al., 2012. Review of the treatment of non-small cell lung cancer with gefitinib. *Clin. Med. Insights Oncol.* 6: 407–421. doi:10.4137/CMO.S7340
- Asdar, M.A., 2019. Efikasi gefitinib dan erlotinib pada pasien adenokarsinoma paru dengan mutasi gen epidermal growth factor receptor di Rumah Sakit Rujukan Respirasi Nasional Persahabatan Jakarta = Efficacy of gefitinib and erlotinib for lung adenocarcinoma with epidermal .
- Barry, M.J., & Edgman-Levitan, S., 2012. Shared Decision Making — The Pinnacle of Patient-Centered Care. *N. Engl. J. Med.* 366: 780–781. doi:10.1056/nejmp1109283
- Blumenthal, G.M., Karuri, S.W., Zhang, H., Zhang, L., Khozin, S., Kazandjian, D., et al., 2015. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. *J. Clin. Oncol.* 33: 1008–1014. doi:10.1200/JCO.2014.59.0489
- Budha, N.R., Frymoyer, A., Smelick, G.S., Jin, J.Y., Yago, M.R., Dresser, M.J., et al., 2012. Drug absorption interactions between oral targeted anticancer agents and PPIs: Is pH-dependent solubility the achilles heel of targeted therapy. *Clin. Pharmacol. Ther.* 92: 203–213. doi:10.1038/clpt.2012.73
- Cancer Council, 2024. Understanding Lung Cancer A guide for people with cancer, their families and friends.
- Chai, C.S., Liam, C.K., Siong, K.K., & Pang, Y.K., 2016. Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma.
- Chan, Y., 2018. Lung cancer clinical findings and paraneoplastic syndromes.
- Chen, W., Miao, J., Wang, Y., Xing, W., Xu, X., & Wu, R., 2023. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis. *Front. Pharmacol.* 14: 1–16. doi:10.3389/fphar.2023.1212313

- Cusatis, G., Gregorc, V., Li, J., Spreafico, A., Ingersoll, R.G., Verweij, J., et al., 2006. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. *J. Natl. Cancer Inst.* 98: 1739–1742. doi:10.1093/jnci/djj469
- Douillard, J.Y., Ostoros, G., Cobo, M., Ciuleanu, T., McCormack, R., Webster, A., et al., 2014. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: A phase-IV, open-label, single-arm study. *Br. J. Cancer* 110: 55–62. doi:10.1038/bjc.2013.721
- Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al., 2009. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur. J. Cancer* 45: 228–247. doi:10.1016/j.ejca.2008.10.026
- Ettinger, D.S., Wood, D.E., Aisner, D.L., Akerley, W., Bauman, J.R., Bharat, A., et al., 2022. Non-Small Cell Lung Cancer, Version 3.2022. *JNCCN J. Natl. Compr. Cancer Netw.* 20: 497–530. doi:10.6004/jnccn.2022.0025
- FDA, 2018. Full Prescribing Information Iressa, IRESSA.
- FDA, 2010. Full Prescribing Information Tarceva [WWW Document].
- Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., et al., 2011. Definition and classification of cancer cachexia: An international consensus. *Lancet Oncol.* 12: 489–495. doi:10.1016/S1470-2045(10)70218-7
- Fernandez, D.C., Pina, P.S., Turcott, J.G., Tapia, N.C., Flores, E.C., Cardona, A.F., et al., 2023. Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma. *Med. Oncol.* 15.
- Gong, Y., Kehl, K.L., Oxnard, G.R., Khozin, S., Kalyani, P.S.M., & Blumenthal, G.M., 2018. Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): A pooled analysis of 8 trials. *J. Clin. Oncol.* 36. doi:https://doi.org/10.1200/JCO.2018.36.15\_suppl.9064
- Gridelli, C., De Marinis, F., Cappuzzo, F., Di Maio, M., Hirsch, F.R., Mok, T., et al., 2014. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: Results of an International expert panel meeting of the Italian association of thoracic oncology. *Clin. Lung Cancer.* doi:10.1016/j.clcc.2013.12.002
- Gridelli, C., de Marinis, F., Di Maio, M., Ardizzoni, A., Belani, C.P., Cappuzzo, F., et al., 2012. Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. *Lung Cancer* 76: 269–279. doi:10.1016/j.lungcan.2011.12.011
- Hanahan, D., & Weinberg, R.A., 2011. Hallmarks of cancer: The next generation. *Cell* 144: 646–674. doi:10.1016/j.cell.2011.02.013
- Herth, F.J.F., 2011. Bronchoscopic techniques in diagnosis and staging of lung cancer. *Breathe* 7: 324–337. doi:10.1183/20734735.021510

- Hidalgo, B.M., Siu, L.L., Nemunaitis, J., Rizzo, J., Hammond, L.A., Takimoto, C., et al., 2001. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies 19: 3267–3279.
- Hirsch, F.R., Suda, K., Wiens, J., & Bunn, P.A., 2016. New and emerging targeted treatments in advanced non-small-cell lung cancer. *Lancet* 388: 1012–1024. doi:10.1016/S0140-6736(16)31473-8
- Hoekstra, R., Dumez, H., Eskens, F.A.L.M., Van Der Gaast, A., Planting, A.S.T., De Heus, G., et al., 2005. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. *Clin. Cancer Res.* 11: 6908–6915. doi:10.1158/1078-0432.CCR-05-0720
- Inoue, A., Saijo, Y., Maemondo, M., Gomi, K., Tokue, Y., Kimura, Y., et al., 2003. Severe acute interstitial pneumonia and gefitinib. *Lancet* 361: 137–139. doi:10.1016/S0140-6736(03)12190-3
- Kane, B., & Luz, S., 2009. Achieving Diagnosis by Consensus. *Comput. Support. Coop. Work* 18(4): 357–392. doi:10.1007/s10606-009-9094-y
- Kemenkes, 2023. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Paru.
- Kim, E.S., Hirsh, V., Mok, T., Socinski, M.A., Gervais, R., Wu, Y.L., et al., 2008. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. *Lancet* 372: 1809–1818. doi:10.1016/S0140-6736(08)61758-4
- Kim, J., Lee, H., & Huang, B.W., 2022. Lung Cancer: Diagnosis, Treatment Principles, and Screening. *Med. World (New York)*.
- Kim, M., Park, G.S., Lee, K.Y., Moon, S.W., & Sung, Y.E., 2025. Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker. *Thorac. Cancer* 16. doi:10.1111/1759-7714.70058
- Kobayashi, H., Sato, K., Niioka, T., Takeda, M., Okuda, Y., Asano, M., et al., 2016. Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib. *Med. Oncol.* 33. doi:10.1007/s12032-016-0773-5
- Lacouture, M.E., 2006. Mechanisms of cutaneous toxicities to EGFR inhibitors. *Nat. Rev. Cancer* 6: 803–812. doi:10.1038/nrc1970
- Laitupa, A.A., & Wulandari, L., 2019. Perbandingan Efikasi Gefitinib dan Erlotinib pada Pasien Kanker Paru Jenis Karsinoma Bukan Kel kecil di Poli Onkologi Satu Atap RS dr Soetomo surabaya. *Repos. Univ. Airlangga*.
- Li, J., Zhao, M., He, P., Hidalgo, M., & Baker, S.D., 2007. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. *Clin. Cancer Res.* 13: 3731–3737. doi:10.1158/1078-0432.CCR-07-0088

- Li, T., & Perez-Soler, R., 2009. Skin toxicities associated with epidermal growth factor receptor inhibitors. *Target. Oncol.* 4: 107–119. doi:10.1007/s11523-009-0114-0
- Lin, J., & Fernandez, F., 2018. Indications for invasive mediastinal staging for non-small cell lung cancer. *J. Thorac. Cardiovasc. Surg.* 156: 2319–2324. doi:10.1016/j.jtcvs.2018.07.027
- Lindeman, N.I., Cagle, P.T., Aisner, D.L., Arcila, M.E., Beasley, M.B., Bernicker, E.H., et al., 2018. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the . *J. Mol. Diagnostics* 20: 129–159. doi:10.1016/j.jmoldx.2017.11.004
- Ling, J., Fettner, S., Lum, B.L., Riek, M., & Rakhit, A., 2008. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. *Anticancer. Drugs* 19: 209–216. doi:10.1097/CAD.0b013e3282f2d8e4
- Liu, H. bing, Wu, Y., Lv, T. feng, Yao, Y. wen, Xiao, Y. ying, Yuan, D. mei, et al., 2013. Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. *PLoS One* 8. doi:10.1371/journal.pone.0055128
- Madke, B., Gole, P., Kumar, P., & Khopkar, U., 2014. Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: ‘PRIDE’ Complex. *Indian J. Dermatol.* May-Jun;59: 271–274. doi:10.4103/0019-5154.13139
- Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., et al., 2010. Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. *N. Engl. J. Med.* 362: 2380–2388. doi:10.1056/nejmoa0909530
- Medscape, 2024. Gefitinib [WWW Document]. URL <https://reference.medscape.com/drug/iressa-gefitinib-1000036#10> (accessed 1.15.24).
- Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., et al., 2010. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol.* 11: 121–128. doi:10.1016/S1470-2045(09)70364-X
- Mohan, A., Madan, K., Hadda, V., Tiwari, P., Mittal, S., Guleria, R., et al., 2019. Guidelines for Diagnostic Flexible Bronchoscopy in Adults: Joint Indian Chest Society/National College of Chest Physicians (I)/Indian Association for Bronchology Recommendations. India.
- Mok, T.S., Wu, Y.-L., Ahn, M.-J., Garassino, M.C., Kim, H.R., Ramalingam, S.S., et al., 2017. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive

- Lung Cancer . *N. Engl. J. Med.* 376: 629–640. doi:10.1056/nejmoa1612674
- Mok, T.S., Wu, Y., Thongprasert, S., Yang, C., Saijo, N., Sunpaweravong, P., et al., 2009. new england journal 947–957.
- Muscaritoli, M., Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., et al., 2021. ESPEN practical guideline: Clinical Nutrition in cancer. *Clin. Nutr.* 40: 2898–2913. doi:10.1016/j.clnu.2021.02.005
- NCCN, 2023. Early and Locally Advanced Non-Small Cell Lung Cancer [WWW Document]. URL <https://www.nccn.org/patients/guidelines/content/PDF/lung-early-stage-patient.pdf>
- Passaro, A., Mok, T., Peters, S., Popat, S., Ahn, M.J., & de Marinis, F., 2021. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. *J. Thorac. Oncol.* 16: 764–773. doi:10.1016/j.jtho.2020.12.002
- Peters, S., Zimmermann, S., & Adjei, A.A., 2014. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions. *Cancer Treat. Rev.* 40: 917–926. doi:10.1016/j.ctrv.2014.06.010
- Pirker, R., Herth, F.J.F., Kerr, K.M., Filipits, M., Taron, M., Gandara, D., et al., 2010. Consensus for EGFR mutation testing in non-small cell lung cancer: Results from a European workshop. *J. Thorac. Oncol.* 5: 1706–1713. doi:10.1097/JTO.0b013e3181f1c8de
- Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E.F., Faivre-Finn, C., et al., 2019. Corrigendum: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2018) 29 (iv192–iv237) DOI: 10.1093/annonc/mdy275). *Ann. Oncol.* 30: 863–870. doi:10.1093/annonc/mdy474
- Polin, R.A., Carlo, W.A., Papile, L.A., Tan, R., Kumar, P., Benitz, W., et al., 2014. Surfactant replacement therapy for preterm and term neonates with respiratory distress. *Pediatrics* 133: 156–163. doi:10.1542/peds.2013-3443
- Pritami, A.A., Ariza, R., Soemarwoto, S., & Wintoko, R., 2022. Faktor Risiko Kanker Paru : Tinjauan Pustaka Risk Factors of Lung Cancer : Literature Review. *Agromedicine* 9: 120–123.
- Putri, A., Pratiwi, S.E., & Musawaris, R.F., 2023. Characteristics of Lung Cancer Patients at Dr. Soedarso Hospital Pontianak from 2017 to 2019. *Indones. J. Cancer* 17: 101. doi:10.33371/ijoc.v17i2.950
- Reck, M., Popat, S., Reinmuth, N., Ruyscher, D. De, Kerr, K.M., & Peters, S., 2014. clinical practice guidelines Clinical Practice Guidelines for diagnosis , treatment clinical practice guidelines. *Ann. Oncol.* 25: iii27–iii39.
- Riely, G.J., Pao, W., Pham, D.K., Li, A.R., Rizvi, N., Venkatraman, E.S., et al., 2006. Clinical course of patients with non-small cell lung cancer and

epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. *Clin. Cancer Res.* 12: 839–844. doi:10.1158/1078-0432.CCR-05-1846

Riely, G.J., Wood, D.E., Ettinger, D.S., Aisner, D.L., Akerley, W., Bauman, J.R., et al., 2024. Non-Small Cell Lung Cancer, Version 4.2024. *JNCCN J. Natl. Compr. Cancer Netw.* 22: 249–274. doi:10.6004/jnccn.2204.0023

Rivera, M.P., Mehta, A.C., & Wahidi, M.M., 2013. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. *Chest* 143: e142S-e165S. doi:10.1378/chest.12-2353

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., et al., 2012. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 13: 239–246. doi:10.1016/S1470-2045(11)70393-X

Sequist, L. V., Martins, R.G., Spigel, D., Grunberg, S.M., Spira, A., Jänne, P.A., et al., 2008. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. *J. Clin. Oncol.* 26: 2442–2449. doi:10.1200/JCO.2007.14.8494

Shao, Y.Y., Shau, W.Y., Lin, Z.Z., Chen, H.M., Kuo, R., Yang, J.C.H., et al., 2013. Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. *Eur. J. Cancer* 49: 106–114. doi:10.1016/j.ejca.2012.07.014

Shi, Y., Au, J.S.K., Thongprasert, S., Srinivasan, S., Tsai, C.M., Khoa, M.T., et al., 2014. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). *J. Thorac. Oncol.* 9: 154–162. doi:10.1097/JTO.0000000000000033

Shimamura, S.S., Shukuya, T., Asao, T., Hayakawa, D., Kurokawa, K., Xu, S., et al., 2022. Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? *BMC Cancer* 22: 1–10. doi:10.1186/s12885-022-09421-7

Song, Z., & Zhang, Y., 2016. Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancer. *Arch. Med. Sci.* 12: 107–111. doi:10.5114/aoms.2016.57586

Stiggelbout, A.M., Pieterse, A.H., & De Haes, J.C.J.M., 2015. Shared decision making: Concepts, evidence, and practice. *Patient Educ. Couns.* 98: 1172–1179. doi:10.1016/j.pec.2015.06.022

Suharti, C., & Suhandiman, I., 2019. Apa Itu Kanker Paru Bukan Sel Kecil? ISHMO.

- Sutandyo, N., Hanafi, A., & Jayusman, M., 2019. Comparison of effectiveness of gefitinib, erlotinib, and afatinib in advanced non-small cell lung cancer patients with EGFR mutation positive in Indonesian population. *Chinese J. Lung Cancer* 22: 562–567. doi:10.3779/j.issn.1009-3419.2019.09.02
- Svedberg, A., Vikingsson, S., Vikström, A., Hornstra, N., Kentson, M., Branden, E., et al., 2019. Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients. *Br. J. Clin. Pharmacol.* 85: 1704–1709. doi:10.1111/bcp.13953
- Thomas, P., Vincent, B., George, C., Joshua, J.M., Pavithran, K., & Vijayan, M., 2019. A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients. *Indian J. Med. Res.* 150: 67–72. doi:10.4103/ijmr.IJMR\_1896\_17
- Tisdale, M.J., 2009. Mechanisms of cancer cachexia. *Physiol. Rev.* 89: 381–410. doi:10.1152/physrev.00016.2008
- Travis, W.D., Brambilla, E., Burke, A.P., Marx, A., & Nicholson, A.G., 2015. Introduction to the 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. *J. Thorac. Oncol.* 10: 1240–1242. doi:10.1097/JTO.0000000000000663
- Vogel, W.H., & Paul, J., 2016. Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer. *J. Adv. Pract. Oncol.* 7: 723–735. doi:10.6004/jadpro.2016.7.7.4
- Weinstein, I.B., & Joe, A., 2008. Oncogene addiction. *Cancer Res.* 68: 3077–3080. doi:10.1158/0008-5472.CAN-07-3293
- WHO, 2021. Indonesia GLOBOCAN 2020 [WWW Document]. URL <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-factsheets.pdf>
- Wu, Y.L., Zhou, C., Hu, C.P., Feng, J., Lu, S., Huang, Y., et al., 2014. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. *Lancet Oncol.* 15: 213–222. doi:10.1016/S1470-2045(13)70604-1
- Zhang, W., Wei, Y., Yu, D., Xu, J., & Peng, J., 2018. Gefitinib provides similar effectiveness and improved safety than erlotinib for East Asian populations with advanced non-small cell lung cancer: A meta-analysis. *BMC Cancer* 18: 1–14. doi:10.1186/s12885-018-4685-y
- Zhao, S., Zhang, Zhen, Fang, W., Zhang, Y., Zhang, Zhonghan, Hong, S., et al., 2020. Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study. *Front. Oncol.* 10: 1–9. doi:10.3389/fonc.2020.587849
- Zhou, 2023. Sample Size Calculation for Survival Endpoint [WWW Document].

URL <https://biostatistics.mdanderson.org/shinyapps/Nsurvival/> (accessed 1.15.24).

Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., et al., 2011. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol.* 12: 735–742. doi:10.1016/S1470-2045(11)70184-X